6660.HK
AIM Vaccine announced Friday that its shares were selected for inclusion in the MSCI Global Small Cap Index, effective after markets closed on Nov. 30.

The latest: AIM Vaccine Co. Ltd. (6660.HK), China’s second-largest maker of non-Covid vaccines, announced Friday that its shares were selected for inclusion in the MSCI Global Small Cap Index, effective after markets closed on Nov. 30.

Looking up: The company believes inclusion in the index will expand its visibility in international capital markets, and bring in a more diversified investor base to boost its trading volume.

Take Note: Companies included MSCI indices are bought and held by exchange-traded funds (ETFs) tracking those indices. But future adjustments, such as a reduction in the proportion or exclusion of a company’s shares, may pressure its stock price.

Digging Deeper: AIM Vaccine has traveled a bumpy road to becoming a listed company. It filed to list on Shanghai’s Nasdaq-style STAR Market in 2020, but later abandoned that effort. In June 2021, it shifted its IPO destination to Hong Kong, but its application was rejected less than a month later. In September that same year, it filed a second time for a Hong Kong listing, but that application lapsed six months later. The company finally made the cut on its third try, passing a hearing in September 2022 and debuting a month afterwards.

Market Reaction: AIM Vaccine’s shares fell on Friday to close down 3.4% at HK$8.49 by the midday break. It now trades at the lower end of its 52-week range.

Translation by A. Au

Have a great investment idea but don’t know how to spread the word? We can help! Contact us for more details.

To subscribe to Bamboo Works weekly free newsletter, click here

Tags:

AIM Vaccine, Non-Covid vaccines, STAR Market, Hong Kong Stock Exchange, ETF

Recent Articles

Should Daqo privatize?

Now all grown up, should Daqo consider privatizing?

The polysilicon maker has more than enough cash to purchase all of its outstanding shares, as its stock remains stubbornly undervalued by investors Key Takeaways: Daqo’s output rose 80% in…
The pharmaceutical company’s profits have been buffeted by erratic returns on an equity stake in a fellow developer of innovative drugs.

Profit setback for Simcere Pharma in novel drugs quest

The pharmaceutical company’s profits have been buffeted by erratic returns on an equity stake in a fellow developer of innovative drugs Key Takeaways: Simcere Pharmaceutical holds a 9% stake in…